scispace - formally typeset
P

Peggy Yena

Researcher at National Institutes of Health

Publications -  17
Citations -  40090

Peggy Yena is an academic researcher from National Institutes of Health. The author has contributed to research in topics: DNA methylation & Gene. The author has an hindex of 17, co-authored 17 publications receiving 32767 citations.

Papers
More filters
Journal ArticleDOI

Comprehensive molecular portraits of human breast tumours

Daniel C. Koboldt, +355 more
- 04 Oct 2012 - 
TL;DR: The ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity.
Journal ArticleDOI

Comprehensive molecular characterization of human colon and rectal cancer

Donna M. Muzny, +320 more
- 19 Jul 2012 - 
TL;DR: Integrative analyses suggest new markers for aggressive colorectal carcinoma and an important role for MYC-directed transcriptional activation and repression.

Integrated genomic analyses of ovarian carcinoma

Daphne W. Bell, +261 more
TL;DR: The Cancer Genome Atlas project has analyzed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours as mentioned in this paper.
Journal ArticleDOI

Comprehensive genomic characterization of squamous cell lung cancers

Peter S. Hammerman, +345 more
- 27 Sep 2012 - 
TL;DR: It is shown that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour.
Journal ArticleDOI

Comprehensive genomic characterization of head and neck squamous cell carcinomas

Michael S. Lawrence, +309 more
- 29 Jan 2015 - 
TL;DR: It is shown that human-papillomavirus-associated tumours are dominated by helical domain mutations of the oncogene PIK3CA, novel alterations involving loss of TRAF3, and amplification of the cell cycle gene E2F1.